• The cost of multiple sclerosis in Norway – (and how certain can we be?) 

      Svendsen, Bjørn; Myhr, Kjell-Morten; Nyland, Harald Inge; Aarseth, Jan Harald (Discussion paper, Working paper, 2006-08)
      The research question initially formulated for this study was to attempt to set a numerical target for the total yearly cost of MS to the Norwegian society, and relate the cost and patients´ experienced quality of life to ...
    • Kostnaden for Norge ved multippel sklerose : og hvor sikre kan vi være? : del I : kostnadstallfestingen 

      Svendsen, Bjørn (Rapport, Research report, 2005-10)
      Multippel sklerose (MS) er en kronisk og potensielt invalidiserende sykdom. Den bryter gjerne ut tidlig i livet og regnes som den nest vanligste årsaken til uførhet blant unge og middelaldrende personer. Den kan også ha ...
    • The cost of multiple sclerosis in Norway 

      Svendsen, Bjørn; Myhr, Kjell-Morten; Nyland, Harald Inge; Aarseth, Jan Harald (Journal article; Peer reviewed, 2010)
      Health economic aspects have been increasingly important during introduction of new treatments for multiple sclerosis. As a partial response for Norway, a costof- illness study was carried out to estimate the yearly ...
    • The economic impact of multiple sclerosis to the patients and their families in Norway 

      Svendsen, Bjørn; Grytten, Nina; Bø, Lars; Aarseth, Hallvard Gilje; Smedal, Tori; Myhr, Kjell-Morten (Journal article; Peer reviewed, 2018)
      Background Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. Objective We aimed to estimate the magnitude of these economic costs in ...
    • Økonomisk analyse av behandling av MS-pasienter med Tysabri® i Norge 

      Svendsen, Bjørn; Aarseth, Jan Harald; Nyland, Harald Inge; Myhr, Kjell-Morten (Rapport, Research report, 2007-05)
      Økonomien i behandling av personer med multippel sklerose med Tysabri® er analysert. Hovedkonklusjonen er at behandling med Tysabri® mest sannsynlig vil gi reduserte kostnader for samfunnet og økte helsegevinster for ...